Figure 1
Treg lines expanded with cell-based aAPCs have equivalent purity and expansion, with increased suppressive function. (A) Representative example (i) and summary (ii) of the CD4, CD25 versus Foxp3 (CD4-gated), and CD127 versus Foxp3 (CD4-gated) profiles for purified cord blood cells expanded 21 days in vitro with bead- or cell-based aAPCs. (B) Representative example (i) and summary (ii) of in vitro expansion of total cells or Tregs (CD4+, CD127−, Foxp3+). Representative example (C) and summary (D) demonstrating that cord blood Tregs expanded with aAPCs potently suppress an in vitro MLR assay (average values for Treg-to-Tresponder ratio of 1:4), and cell-based aAPCs are even more effective than bead-based aAPCs. For each summary, the data are presented as the mean plus or minus the standard error of the mean (SEM), with n = 7. *P ≤ .05.

Treg lines expanded with cell-based aAPCs have equivalent purity and expansion, with increased suppressive function. (A) Representative example (i) and summary (ii) of the CD4, CD25 versus Foxp3 (CD4-gated), and CD127 versus Foxp3 (CD4-gated) profiles for purified cord blood cells expanded 21 days in vitro with bead- or cell-based aAPCs. (B) Representative example (i) and summary (ii) of in vitro expansion of total cells or Tregs (CD4+, CD127−, Foxp3+). Representative example (C) and summary (D) demonstrating that cord blood Tregs expanded with aAPCs potently suppress an in vitro MLR assay (average values for Treg-to-Tresponder ratio of 1:4), and cell-based aAPCs are even more effective than bead-based aAPCs. For each summary, the data are presented as the mean plus or minus the standard error of the mean (SEM), with n = 7. *P ≤ .05.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal